CBPO  China Biologic Products Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

3.11B

Vuru Grade

72.45/100

Current Price

$114.74
-0.06 (-0.05%)

Growth Price

$38.94
Overvalued by 66.06%

Stability Price

$21.69
Overvalued by 81.10%

Company Metrics

  • P/E 31.46
  • P/S 9.39
  • P/B 6.55
  • EPS 3.65
  • Cash ROIC 27.80%
  • Cash Ratio 2.02
  • Dividend 0 / N/A %
  • Avg. Vol. 190,698.00
  • Shares 27.10M
  • Market Cap. 3.11B

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

British Airways Pensions Investment Management Ltd Has $9690000 Stake in China ...
The Cerbat Gem - 50 minutes ago
British Airways Pensions Investment Management Ltd reduced its stake in China Biologic Products Inc. (NASDAQ:CBPO) by 27.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
Should You Follow Hedge Funds Into China Biologic Products Inc (CBPO)?
Insider Monkey (blog) - Dec 1, 2016
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.
China Biologic Products, Inc. (NASDAQ:CBPO) PEG Ratio At 1.41 - Equities Focus
CBPO Makes Notable Cross Below Critical Moving Average - Nasdaq
Today's Rating Sentiment Change: Can analysts adopt a bullish outlook for ...
MoneyMakingArticles - Dec 2, 2016
Out of 2 analysts covering China Biologic Products (NASDAQ:CBPO), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive.
Despite Recent Market Upturn, This Stock Struggled This Week: China Biologic ...
CSZ News - Dec 4, 2016
China Biologic Products, Inc. (NASDAQ:CBPO) stock has moved in a downward direction over the past week, yielding losses for investors after the elections concluded.
China Biologic Products Inc. (CBPO) Lowered to Hold at Zacks Investment Research
The Cerbat Gem - Oct 11, 2016
China Biologic Products logo China Biologic Products Inc. (NASDAQ:CBPO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.
Icon Advisers Inc. Co. Invests $1929000 in China Biologic Products Inc. (CBPO)
BBNS - Nov 30, 2016
China Biologic Products logo Icon Advisers Inc. Co. acquired a new position in China Biologic Products Inc. (NASDAQ:CBPO) during the third quarter, according to its most recent filing with the SEC.
$0.83 EPS Expected For China Biologic Products, Inc. (NASDAQ:CBPO) In Quarter - Markets Daily
Which Analysts Are Watching China Biologic Products, Inc. (NASDAQ:CBPO)? - Fiscal Standard
China Biologic Products Inc. (CBPO) Issues Earnings Results
The Cerbat Gem - Nov 3, 2016
China Biologic Products logo China Biologic Products Inc. (NASDAQ:CBPO) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $1.22 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate ...
China Biologic Products Inc. Reports 31% Increase In Q3 Profit - RTT News
China Biologic Products Inc. (CBPO) Posts Quarterly Earnings Results, Beats ... - DailyQuint
Today, China Biologic Products Inc. (CBPO) Downgraded by Zacks Investment ...
DailyQuint - Nov 30, 2016
Zacks Investment Research lowered shares of China Biologic Products Inc. (NASDAQ:CBPO) from a buy rating to a hold rating in a research report released on Tuesday.
China Biologic Announces Secondary Offering of Common Stock
PR Newswire (press release) - Mar 1, 2016
BEIJING, March 1, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that Warburg Pincus Private Equity X, L.P.
China Biologic Products (CBPO) Prices 3.87M Common Secondary Offering at $110 ... - StreetInsider.com
Warburg Pincus to offload 3.5 mln China Biologic shares in secondary offering - Thomson Reuters' peHUB (press release)
Stocks End Week in Red, But This One Bucking Trend: China Biologic Products ...
AR News - Dec 4, 2016
Wall Street ended Friday on a mixed note, with the Dow Jones Industrial Average hovering in the red where it spent most of the session, while the S&P 500 and the Nasdaq Composite just managed to hang on to gains after fluctuating earlier in the day ...